Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A platform partnership
January 2020
SHARING OPTIONS:

SCHLIEREN, Switzerland & SAN FRANCISCO—Late last year, Akero Therapeutics selected InSphero AG’s 3D InSight Human Liver Disease platform to characterize AKR-001’s physiological effects in different kinds of liver cells. This effort will evaluate AKR-001’s effects on liver metabolism, NASH-induced liver fibrosis, and pathways related to stress and cell death of hepatocytes, among other effects. AKR-001 is a novel, long-acting FGF21 analog being developed for the treatment of NASH.
 
“We believe AKR-001 has unique potential among investigational NASH therapies to restore whole-body metabolic balance while also acting directly to reduce inflammation and fibrotic scarring in the liver,” commented Tim Rolph, chief scientific officer and co-founder of Akero. “With InSphero’s human in-vitro liver disease platform, we will evaluate AKR-001’s effects on human liver cells to help contextualize results from our ongoing Phase 2a clinical trial.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.